Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTUNASDAQ:CYCNNASDAQ:GRAYNASDAQ:PHIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$1.95$1.49$0.95▼$2.99$12.03M0.05367,015 shs94,423 shsCYCNCyclerion Therapeutics$3.11+0.3%$3.02$1.27▼$9.47$9.98M1.581.28 million shs9,411 shsGRAYGraybug Vision$1.72-1.7%$1.73$5.00▼$22.12$2.70M1.22,165 shs7,837 shsPHIOPhio Pharmaceuticals$2.27-8.1%$2.06$0.97▼$9.79$10.89M0.842.45 million shs262,924 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma0.00%-2.50%+44.44%+61.84%-34.34%CYCNCyclerion Therapeutics+0.32%-2.20%+1.97%+22.92%+37.00%GRAYGraybug Vision-3.31%+4.17%-9.33%-11.62%-66.54%PHIOPhio Pharmaceuticals-8.10%-23.31%+22.04%+75.97%-64.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYTUAytu BioPharma1.4895 of 5 stars0.04.00.03.43.10.00.6CYCNCyclerion Therapeutics1.6724 of 5 stars0.03.00.00.03.33.30.6GRAYGraybug VisionN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals3.8482 of 5 stars3.55.00.00.03.32.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 0.00N/AN/AN/ACYCNCyclerion Therapeutics 0.00N/AN/AN/AGRAYGraybug Vision 0.00N/AN/AN/APHIOPhio Pharmaceuticals 3.00Buy$14.00516.74% UpsideCurrent Analyst Ratings BreakdownLatest GRAY, CYCN, PHIO, and AYTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$81.66M0.15N/AN/A$4.64 per share0.42CYCNCyclerion Therapeutics$2.08M4.80N/AN/A$4.62 per share0.67GRAYGraybug VisionN/AN/AN/AN/A$1.67 per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$18.57 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A-7.62%-19.30%-4.80%N/ACYCNCyclerion Therapeutics-$5.26M-$1.16N/A∞N/AN/A-55.32%-48.35%8/6/2025 (Estimated)GRAYGraybug Vision-$35.60M-$24.23N/AN/AN/AN/A-77.61%-71.34%N/APHIOPhio Pharmaceuticals-$10.83M-$10.92N/A0.60N/AN/A-134.57%-108.39%8/13/2025 (Estimated)Latest GRAY, CYCN, PHIO, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AGRAYGraybug VisionN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.320.980.81CYCNCyclerion TherapeuticsN/A5.075.07GRAYGraybug VisionN/A10.7310.72PHIOPhio PharmaceuticalsN/A6.386.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%CYCNCyclerion Therapeutics75.62%GRAYGraybug Vision49.94%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma3.60%CYCNCyclerion Therapeutics34.30%GRAYGraybug Vision7.94%PHIOPhio Pharmaceuticals0.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma1606.17 million6.00 millionNot OptionableCYCNCyclerion Therapeutics303.21 million1.73 millionNo DataGRAYGraybug Vision271.57 million20.25 millionNot OptionablePHIOPhio Pharmaceuticals104.80 million6.85 millionNot OptionableGRAY, CYCN, PHIO, and AYTU HeadlinesRecent News About These CompaniesFY2025 Earnings Forecast for PHIO Issued By HC WainwrightJune 10, 2025 | americanbankingnews.comQ2 Earnings Estimate for PHIO Issued By HC WainwrightJune 8, 2025 | americanbankingnews.comHC Wainwright Begins Coverage on Phio Pharmaceuticals (NASDAQ:PHIO)June 7, 2025 | americanbankingnews.comPhio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA PortfolioJune 6, 2025 | newsfilecorp.comBest Value Stocks to Buy for May 28thMay 28, 2025 | zacks.comNew Strong Buy Stocks for May 28thMay 28, 2025 | zacks.comPhio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor ConferenceMay 19, 2025 | newsfilecorp.comPhio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | newsfilecorp.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical TrialMay 7, 2025 | finanznachrichten.dePhio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical TrialMay 7, 2025 | newsfilecorp.comPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMay 1, 2025 | newsfilecorp.comBest Momentum Stocks to Buy for April 23rdApril 23, 2025 | zacks.comBest Value Stocks to Buy for April 23rdApril 23, 2025 | zacks.comPhio Pharmaceuticals Corp. Common StockApril 12, 2025 | fxempire.comPhio Pharmaceuticals announces Safety Monitoring Committee recommendation to advance INTASYL PH-762 skin cancer studyApril 12, 2025 | pharmabiz.comPhio advances skin cancer treatment with successful trialApril 11, 2025 | uk.investing.comPHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next DoseApril 10, 2025 | zacks.comThis Biotech Is Ripping Following Phase 1b Trial AnnouncementApril 9, 2025 | msn.comPhio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s ThrilledApril 9, 2025 | msn.comPhio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation CohortApril 9, 2025 | newsfilecorp.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRAY, CYCN, PHIO, and AYTU Company DescriptionsAytu BioPharma NASDAQ:AYTU$1.95 0.00 (0.00%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.02 +0.07 (+3.33%) As of 06/13/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Cyclerion Therapeutics NASDAQ:CYCN$3.11 +0.01 (+0.32%) Closing price 06/13/2025 03:55 PM EasternExtended Trading$3.11 0.00 (0.00%) As of 06/13/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Graybug Vision NASDAQ:GRAY$1.72 -0.03 (-1.71%) As of 06/13/2025Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.Phio Pharmaceuticals NASDAQ:PHIO$2.27 -0.20 (-8.10%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.28 +0.00 (+0.22%) As of 06/13/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
